Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
- Market Cap ₹ 145 Cr.
- Current Price ₹ 12.9
- High / Low ₹ 15.8 / 3.76
- Stock P/E
- Book Value ₹ 5.05
- Dividend Yield 0.00 %
- ROCE -12.3 %
- ROE -24.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 74.6 days to 45.4 days
Cons
- Stock is trading at 2.56 times its book value
- Company has low interest coverage ratio.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | |
---|---|---|---|
16.36 | 24.67 | 25.67 | |
17.92 | 25.91 | 27.68 | |
Operating Profit | -1.56 | -1.24 | -2.01 |
OPM % | -9.54% | -5.03% | -7.83% |
0.59 | 1.14 | 1.08 | |
Interest | 0.36 | 0.24 | 0.53 |
Depreciation | 0.48 | 0.43 | 0.43 |
Profit before tax | -1.81 | -0.77 | -1.89 |
Tax % | 4.42% | 11.69% | 2.12% |
-1.89 | -0.86 | -1.93 | |
EPS in Rs | -1.40 | -0.64 | -1.43 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -124% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 92% |
3 Years: | 20% |
1 Year: | 236% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | |
---|---|---|---|
Equity Capital | 12.11 | 12.11 | 12.12 |
Reserves | -2.49 | -3.36 | -5.29 |
3.79 | 3.73 | 2.76 | |
4.74 | 7.01 | 7.76 | |
Total Liabilities | 18.15 | 19.49 | 17.35 |
6.70 | 6.41 | 6.02 | |
CWIP | 0.00 | 0.00 | 0.00 |
Investments | 0.38 | 0.38 | 0.28 |
11.07 | 12.70 | 11.05 | |
Total Assets | 18.15 | 19.49 | 17.35 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | |
---|---|---|---|
-1.66 | 0.39 | 1.29 | |
-1.22 | -0.14 | 0.08 | |
2.97 | -0.28 | -1.43 | |
Net Cash Flow | 0.09 | -0.03 | -0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2006 | Mar 2007 | Mar 2008 | |
---|---|---|---|
Debtor Days | 112.67 | 119.40 | 123.56 |
Inventory Days | 75.70 | 28.81 | 12.58 |
Days Payable | 0.00 | 0.00 | 0.00 |
Cash Conversion Cycle | 188.37 | 148.20 | 136.14 |
Working Capital Days | 110.21 | 68.35 | 45.36 |
ROCE % | -4.09% | -12.32% |
Documents
Announcements
-
Closure of Trading Window
13h - Closure of trading window from January 1, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 Dec - Newspaper Clippings of Postal Ballot Notice and Remote E voting Intimation
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
3 Dec - Postal ballot notice for appointing a new director.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Welcure Drugs & Pharmaceuticals Ltd. Held On Today I.E. Monday, 02Nd December, 2024.
2 Dec - Board approved postal ballot for director appointment.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper Clipping of Unaudited Financials Results of Quarter and Half Year Ended September 30, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.